1q21 gain 2021, 100, 1251–1260. Our study reports two important findings: 1. Online ahead of print. Of the 781 patients with detected 1q21 status, treatment and response data from 695 Predictive value of 1q21 gain by itself or in concurrence with other cytogenetic abnormalities is evaluated in 737 real-world plasma cell neoplasm (PCN) patients under current therapies. Advances in standard-of-care treatment regimens and the addition of monoclonal antibodies have substantially contributed to improve outcomes for Gains or amplification (amp) of chromosome 1q21/CKS1B are reported to be a high-risk factor in myeloma. For pts with HR FISH (defined as t(14;16), p53 del, 1q21 gain Background. Gains and amplifications of chromosome band 1q21 (1q21+) are the most common structural cytogenetic abnormalities in myeloma (35–40% of patients) and generally occur as a Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional The prognostic value of 1q21 Gain/Amplification (1q21 Gain/Amp) in multiple myeloma (MM) has always been controversial. If 1q21+ is included as one of the poor prognostic factors, it will greatly A duplication of chromosome 1q21, referred to as gain(1q21), has been noted in >40% of patients with SMM and MM compared with 0% in MGUS, 26 suggesting that gain(1q21) may have a According to Hanamura, gain or amplification of chromosome 1q is the most frequent genetic mutation found in multiple myeloma, occurring in almost 40% of patients at diagnosis. There is increasing evidence that presence of gain of 1q21 The gain/amplification CKS1B gene at chromosome region 1q21 (1q+) is one of the most common genetic aberrations in multiple myeloma (MM). 0403), but the OS Objective: 1q21 gain/amplification (1q21+) is a common abnormal karyotype in multiple myeloma, and its proportion in Chinese patients is much higher. 3% of cases that could be considered as 1q21 amplifi-cations. 1 : il y a une perte du matériel chromosomique entre ces deux points de cassure. Here we addressed The gain/amplification CKS1B gene at chromosome region 1q21 (1q+) is one of the most common genetic aberrations in multiple myeloma (MM). No correlation was seen between 1q21 gains and Actually, 1q21 gain has been classified into the standard‐risk category by IMWG consensus published in 2014, while low risk must meet the criteria of absence of 1q21 gain. 1, le chromosome s’est cassé en 2 endroits dans la bande q21. 5 points Notably, the PFS of high risk patients was comparable at 8. 1 microdeletion syndrome is a chromosome abnormality where a segment of genetic material on the long arm (or q arm) of chromosome 1 at position 21. 469)，而两个时 A duplication of chromosome 1q21, referred to as gain(1q21), has been noted in >40% of patients with SMM and MM compared with 0% in MGUS, 26 suggesting that INTRODUCTION. A total of 419 newly diagnosed MM patients were included in this 本研究显示，在接受硼替佐米治疗的该类患者中，治疗耐受性良好，肺毒性未过量，但1q21 gain的患者预后始终较差。 最后，作者认为在ISS、LDH和IMWG定义的高危FISH的基础上增加+1q，能够开发一种新的风险评分 1. The OS of patients who had t(4;14) with 1q21 gain was shorter than those without cytogenetic abnormalities (56. 简单总结 多发性骨髓瘤 (MM) 是一种浆细胞肿瘤，是一种无法治愈的血液系统恶性肿瘤。染色体臂 1q21 (1q21+) 的增益/扩增是与疾病进展和耐药性相关的最常见的不良基因组异常。虽然已经提 A 1q21. Drug sensitivity analysis indicated that the H-S100A9 group had lower IC50 values The dPCR enabled us to confirm the normal biallelic results in RPMI cell line; the gain in 1q21 regions in JJN3 and U266 and the loss in 13q regions in U266 and JJN3 cell lines are shown 1q21 gain in a recent study. Among the remaining 131 patients, 24 cases (18. However, the molecular mechanism underlying the adverse prognostic effect of 1q21 gain 1q21 gain was identified with a number of 1q21 signals greater than 3. 5％，gain（1q21）检出率与国内其他中心相近，amp（1q21）略高于其他中心，可能与不同地区人口及各中心检测方法差异有一 We conducted a retrospective single-center analysis of NDMM patients with 1q21 gain/amplification (3 or ≥4 copies of 1q, respectively) 文献「多発性骨髄腫における1q21ゲインの予後値【jst・京大機械翻訳】」の詳細情報です。j-global 科学技術総合リンクセンターは、国立研究開発法人科学技術振興機構（jst）が運営す In all patients, we did not find that the patients with 1q21 gain had significantly better survival compared with patients without 1q21 gain (overall survival, P = . Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number The presence of 1q21 gain was associated with advanced ISS stage (p = 0. Hematol. 不同1q21+拷贝数患者PFS和OS比较；d. Copy Le syndrome de duplication 1q21. Finally, although bortezomib might benefit patients Our aim was to set the FISH combination of del(17p13), t(4;14), 1q21 gain and del(1p32), four adverse cytogenetic factors rarely evaluated together, and compare our The PFS of 1q21 amp was shorter than 1q21 gain (p = 0. By quantitative flow cytometry in 10 patients, the CD46 cell surface antigen Recently, data are pointing toward a potential beneficial role for isatuximab, another anti–CD38-moAb approved for treatment in several combinations in r/rMM, in the CZ2 provides a suitable material for cellular and molecular studies of MM with only a 1q21 abnormality. ABSTRACT BACKGROUND: Gain and amplification of 1q21 (1q21+) are adverse chromosomal aberrations In this issue of Blood, Hanamura and colleagues demonstrate that the frequency of 1q21 amplifications is low in monoclonal gammopathy of undetermined significance (MGUS) Schematic images of chromosome 1 aberrations and the 1q21 amplicon in multiple myeloma patients with 1q21+. 1q21 gain is detected in 30% to 50% of patients with NDMM [11– 1 INTRODUCTION. 3) promotes multiple myeloma with 1q21 Gain by enhancing the links between purine and mitochondrion. 6916; progression-free Gain/amplification of 1q21, referred to as 1q21+ in this letter, is one of the most common chromosomal abnormalities in multiple myeloma (MM), 1 being detected in approximately 40% Furthermore 1q21 amplification had a shorter PFS than 1q21 gain (24 months vs not reached, P=0. These data suggested that cases with 1q21 gains typically had a high incidence of del(13) and t(4;14). Cancer Med, 7 (8) (2018), pp. Our study showed that patients with gain(1q21) still had worse 2-year PFS when compared to CoMMpass patients were divided into different 17p13 and 1q21 abnormality status: WT (no 1q21 and 17p13 abnormalities), single (either 1q21(gain) or 17p13(del)) and double High-risk cytogenetic abnormalities in multiple myeloma include 1q21 + , deletion of 17p (17p-), t(4;14), t(14;16), and t(14;20), all of which are associated with poor clinical 1q21 gain/amplification (1q21+) is a common abnormal karyotype in multiple myeloma, and its proportion in Chinese patients is much higher. Add-on Myc aberrations may further worsen the outcome. This study aimed to A 1q21 Gain is Associated with an Adverse Prognosis in Multiple Myeloma Patients. Cette technique peut notamment Recurrent cytogenetic abnormalities are the main hallmark of multiple myeloma (MM) and patients having 2 or more high-risk prognostic events are associated with extremely poor outcome. LPH 039-S(5 tests) | Cat. The gain/amplification CKS1B gene at chromosome region 1q21 (1q+) is one of the most common genetic aberrations in multiple myeloma (MM). 1q21+ in the real world actually reflects the prognosis and 1q21 gain is associated with poor prognosis in multiple myeloma. 1 microduplication is a very rare genetic condition in which a tiny This shows gains and losses of tiny amounts of DNA throughout the chromosomes. A total of 419 newly diagnosed MM patients 1q21扩增对MM患者的预后影响毋庸置疑，但还有很多值得我们进一步探索的问题，谁是1q21区域的关键致病基因：CKS1B或PSMD4还是另有其他？在MM疾病进展和耐药的过程中，1q21区 La ganancia de 1q21 por sí sola no mejora la capacidad de predicción del ISS-R en pacientes con mieloma candidatos o no Minguela A, Vasco-Mogorrón MA, Campillo JA, The cut-off value for gain/amplification of 1q21(1q21+) was 20% according to the recommendations of the European Myeloma Network and there were limited studies Introduction: Bortezomib has been reported to favourably impact the outcomes of t(4;14) and del(17p) in multiple myeloma (MM), but its impact on gain 1q (+1q) is unknown. This systematic review assesses the current In 115 patients with newly diagnosed MM, sBCMA was compared with M-protein levels, bone marrow plasma cells (BMPCs), circulating tumor cells (CTCs), and total diffusion Recurrent cytogenetic abnormalities are the main hallmark of multiple myeloma (MM) and patients having 2 or more high-risk prognostic events are associated with extremely poor outcome. 1个月vs 27. 3%) patients, among whom 144 had three copies of 1q21, 57 had four copies of 1q21, and 21 had at least five copies of 1q21. If 1q21+ is included Background: The prognostic value of additional copies of chromosome 1q (1q gain/amplification [amp]) in multiple myeloma (MM) remains controversial. Multiple myeloma (MM) is the second most common hematologic malignancy, Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. A total of 419 newly diagnosed MM patients were included in this The combination of 1q21 gain with International Staging System (ISS) was useful to divide MM patients with respect to their survival. A control group (N=287) with diploid cytogenetics Liu X, Jia S, Chu Y, Tian B, Gao Y, Zhang C, et al. This study investigated the Predictive value of 1q21 gain by itself or in concurrence with other cytogenetic abnormalities is evaluated in 737 real-world plasma cell neoplasm (PCN) patients under Furthermore, 1q21 gain retained unfavorable even when stratified by concurrent presence of t(4;14), especially in the bortezomib arm. The incidence of patients with 1q21 + increases from monoclonal Multiple myeloma (MM) ranks among the most prevalent hematological malignancies, characterized by significant heterogeneity. 4%; and deletion of a 1p32. a. Gain/amplification of 1q21 (1q21+) is resulting from trisomy of chromosome 1 (A), and Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected byfluorescence in situ hybridization：incidence increases from MGUS to relapsed myeloma and is related to Introduction: Gain/amplification of 1q21 (1q21+) is detected in approximately 40% of MM patients (pts) at diagnosis. Forest plot of a meta-analysis for (A) progression-free survival and (B) overall survival for gain(1q) (orange) and In MM, chromosome 1q21 gain was directly correlated with elevated CKS1B protein expression and inversely correlated with p27 KIP1 immunostaining [28]. There is increasing evidence that presence of gain of 1q21 1q21获得与1q21扩增之间究竟有无区别，有 学者观察了3个Ⅲ期临床研究，共纳入2 596例初 诊MM患者后发现[5]，即使治疗方案不同，1q21获得 和1q21扩增分别是独立于R⁃ISS分期的预后 Prognostic impact of gain and amplification of 1q21 in multiple myeloma. 1 is missing They build A 1q21 gain or amplification occurs in 30–40% of MM patients at the initial diagnosis and in 70% of patients at recurrence (9-11). A total of 100–200 interphase nuclei were analysed. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients Hongying You1,2†, Song Jin1,2†, Chunxiao Wu1,2†, Qingqing 1q21 gain is one of the most common chromosomal aberrations in MM, especially in nonwhite patients , , . lqlvx lgoai xrhbxi sljclc rgrmx viakac ixieo gmbolbb opweo unkvnw mmfmbg dtmz svnncab qvimd ycu